Cargando…
Aggressive Posterior Retinopathy of Prematurity: Long-Term Outcomes Following Intravitreal Bevacizumab
PURPOSE: The purpose of this study is to review the neonatal and early childhood course of children who were treated with intravitreal bevacizumab for APROP and identify any long term limitations these children face years after treatment. METHODS: This retrospective consecutive case series reviewed...
Autores principales: | Naravane, Ameay V., Belin, Peter J., Rubino, Shaina, Quiram, Polly A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873379/ https://www.ncbi.nlm.nih.gov/pubmed/35223691 http://dx.doi.org/10.3389/fped.2022.778585 |
Ejemplares similares
-
Intravitreal Ranibizumab for Aggressive Posterior Retinopathy of Prematurity
por: Li, Xiu-Juan, et al.
Publicado: (2016) -
Vitreoretinopathy-Associated Pediatric Retinal Detachment Treatment Outcomes: IRIS® Registry (Intelligent Research in Sight) Analysis
por: Belin, Peter J., et al.
Publicado: (2023) -
Bevacizumab or laser for aggressive posterior retinopathy of prematurity
por: Blair, Michael, et al.
Publicado: (2018) -
Comment on “bevacizumab or laser for aggressive posterior retinopathy of prematurity”
por: Samanta, Ramanuj
Publicado: (2019) -
Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity
por: Nicoară, Simona Delia, et al.
Publicado: (2015)